PTPI vs. CPHI, LIPO, XCUR, ARTL, NEXI, DRUG, OGEN, CING, ENSC, and GNPX
Should you be buying Petros Pharmaceuticals stock or one of its competitors? The main competitors of Petros Pharmaceuticals include China Pharma (CPHI), Lipella Pharmaceuticals (LIPO), Exicure (XCUR), Artelo Biosciences (ARTL), NexImmune (NEXI), Bright Minds Biosciences (DRUG), Oragenics (OGEN), Cingulate (CING), Ensysce Biosciences (ENSC), and Genprex (GNPX). These companies are all part of the "pharmaceutical preparations" industry.
China Pharma (NYSE:CPHI) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.
Petros Pharmaceuticals has a consensus price target of $4.00, suggesting a potential upside of 479.88%. Given China Pharma's higher possible upside, analysts clearly believe Petros Pharmaceuticals is more favorable than China Pharma.
China Pharma has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 2.02, meaning that its share price is 102% more volatile than the S&P 500.
China Pharma has a net margin of -43.91% compared to China Pharma's net margin of -181.87%. Petros Pharmaceuticals' return on equity of -54.53% beat China Pharma's return on equity.
Petros Pharmaceuticals received 1 more outperform votes than China Pharma when rated by MarketBeat users. Likewise, 100.00% of users gave Petros Pharmaceuticals an outperform vote while only 0.00% of users gave China Pharma an outperform vote.
China Pharma has higher revenue and earnings than Petros Pharmaceuticals.
In the previous week, China Pharma had 2 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 2 mentions for China Pharma and 0 mentions for Petros Pharmaceuticals. Petros Pharmaceuticals' average media sentiment score of 0.46 beat China Pharma's score of 0.00 indicating that China Pharma is being referred to more favorably in the media.
12.3% of Petros Pharmaceuticals shares are held by institutional investors. 46.0% of China Pharma shares are held by company insiders. Comparatively, 36.4% of Petros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
China Pharma beats Petros Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get Petros Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PTPI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PTPI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Petros Pharmaceuticals Competitors List
Related Companies and Tools
